Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Colombo, D. Orlic, G. Stanković, N. Corvaja, V. Spanos, M. Montorfano, F. Liistro, M. Carlino, F. Airoldi, A. Chieffo, C. Mario (2003)
Preliminary Observations Regarding Angiographic Pattern of Restenosis After Rapamycin-Eluting Stent ImplantationCirculation: Journal of the American Heart Association, 107
S. Silber, E. Grube, J. Marco, G. Grollier, M. Morice, P. Serruys, M. Cobaugh, W. Wijns (2003)
Direct stent implantation using the EXPRESS Coronary Stent System: results of a multi-center feasibility study.Journal of interventional cardiology, 16 6
H. Lowe, S. Oesterle, L. Khachigian (2002)
Coronary in-stent restenosis: current status and future strategies.Journal of the American College of Cardiology, 39 2
E. Grube (2003)
1495 Everolimus stent coating: promising procedural and 6-month angiographic and intravascular ultrasound follow-up results of the FUTURE I and II trialEuropean Heart Journal, 24
(2004)
Paclitaxel-eluting stents to prevent restenosis and reocclusion after recanalisation of chronic total coronary occlusions: The PACTO study
M. Rotter, D. Pfiffner, W. Maier, A. Zeiher, B. Meier (1996)
Interventional cardiology in Europe 1999.European heart journal, 24 12
J. Armstrong, J. Gunn, N. Arnold, N. Malik, K. Chan, T. Vick, P. Stratford, D. Cumberland, C. Holt (2002)
Angiopeptin-eluting stents: observations in human vessels and pig coronary arteries.The Journal of invasive cardiology, 14 5
P. Teirstein (2001)
Living the dream of no restenosis.Circulation, 104 17
(2003)
Nine-month subgroup analysis of the E-SIRIUS trial: Direct stenting vs predilatation. Circulation, 2003;108(Suppl IV):IV-533
N. Klein (2003)
P2215 Trapidil eluting coronary stent: protection from restenosis without cellular toxicity?European Heart Journal, 24
H. Griffiths, A. Bakhai, D. West, A. Souza, J. Clague, S. Davies, C. Brookes, Andrew Bishop, J. Pepper, C. Mario (2004)
862-6 Stents without restenosis: Enough to replace bypass surgery?Journal of the American College of Cardiology, 43
Silber Silber, Albertsson Albertsson, Avilés Avilés (2004)
European Guidelines for Percutaneous Coronary Interventions (PCI)Eur Heart J
R. Fattori, T. Piva (2003)
Drug-eluting stents in vascular interventionThe Lancet, 361
Saia Saia, Lemos Lemos, Arampatzis Arampatzis (2004)
Clinical and angiographic outcomes after overdilatation of undersized sirolimus‐eluting stents with largely oversized balloons: An observational studyCatheter Cardiovasc Interv, 61
M. Degertekin, C. Arampatzis, P. Lemos, F. Saia, A. Hoye, J. Daemen, K. Tanabe, Chi‐Hang Lee, Sjoerd Hofma, G. Sianos, E. Mcfadden, W. Giessen, P. Smits, P. Feyter, R. Domburg, P. Serruys (2004)
Very long sirolimus-eluting stent implantation for de novo coronary lesions.The American journal of cardiology, 93 7
R. Virmani, F. Liistro, G. Stanković, C. Mario, M. Montorfano, A. Farb, F. Kolodgie, A. Colombo (2002)
Mechanism of Late In-Stent Restenosis After Implantation of a Paclitaxel Derivate–Eluting Polymer Stent System in HumansCirculation: Journal of the American Heart Association, 106
(2003)
One month safety of nonpolymeric Paclitaxel coated nitinol stents in the porcine aorta
C. Arampatzis, P. Lemos, K. Tanabe (2003)
Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease☆Acc Current Journal Review, 12
M. Hong, G. Mintz, Cheol-Whan Lee, Jong-Min Song, K. Han, D. Kang, Jae-Kwan Song, Jae‐Joong Kim, N. Weissman, N. Fearnot, Seong-Wook Park, Seung‐Jung Park (2003)
Paclitaxel Coating Reduces In-Stent Intimal Hyperplasia in Human Coronary Arteries: A Serial Volumetric Intravascular Ultrasound Analysis From the ASian Paclitaxel-Eluting Stent Clinical Trial (ASPECT)Circulation: Journal of the American Heart Association, 107
E. Grube, L. Buellesfeld, R. Mueller, M. Staberock, Guido Selbach, T. Schmidt, U. Gerckens (2003)
First human experience using a new everolimus stent coating: Procedural and six-month follow-up results of the FUTURE trialJournal of the American College of Cardiology, 41
(2003)
Evaluation of vascular effects of simvastatin-eluting stents in porcine coronary arteries at 1 month postimplantation
W. O’Neill, M. Leon (2003)
Drug-eluting stents: costs versus clinical benefit.Circulation, 107 24
A. Abizaid, R. Kornowski, G. Mintz, M. Hong, A. Abizaid, R. Mehran, A. Pichard, K. Kent, L. Satler, Hongsheng Wu, J. Popma, M. Leon (1998)
The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation.Journal of the American College of Cardiology, 32 3
E. Grube, A. Lansky, Nicholas Reitart, J. Fajadet, G. Disciascio, C. Dimario, K. Hauptmann, A. Colombo, R. Bach, S. Silber (2002)
SCORE six-month angiographic results: improved restenosis in patients receiving the QUADDS-QP2 drug-eluting stent compared with the control, bare stentsJournal of the American College of Cardiology, 39
Christophe Bauters, E. Hubert, Alain Prat, Karim Bougrimi, E. Belle, E. McFadden, P. Amouyel, P. Amouyel, J. Lablanche, Michel Bertrand (1998)
Predictors of restenosis after coronary stent implantation.Journal of the American College of Cardiology, 31 6
Takeshi Kimura, H. Yokoi, Y. Nakagawa, Takashi Tamura, Satoshi Kaburagi, Y. Sawada, Yasukazu Sato, Hiroatsu Yokoi, N. Hamasaki, H. Nosaka, M. Nobuyoshi (1996)
Three-year follow-up after implantation of metallic coronary-artery stents.The New England journal of medicine, 334 9
M. Babapulle, M. Eisenberg (2002)
Coated stents for the prevention of restenosis: Part I.Circulation, 106 21
R. Wessely (2003)
P2235 Statins are promising compounds for drug coated stents to prevent restenosis following percutaneous coronary interventionEuropean Heart Journal, 24
A. Finkelstein, D. Mcclean, S. Kar, Kaname Takizawa, K. Varghese, Namjin Baek, K. Park, M. Fishbein, R. Makkar, F. Litvack, N. Eigler (2003)
Local Drug Delivery via a Coronary Stent With Programmable Release PharmacokineticsCirculation: Journal of the American Heart Association, 107
M. Babapulle, M. Eisenberg (2002)
Coated Stents for the Prevention of Restenosis: Part IICirculation: Journal of the American Heart Association, 106
E. Schampaert, E. Cohen, M. Schlüter, F. Reeves, M. Traboulsi, L. Title, R. Kuntz, J. Popma (2004)
The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS).Journal of the American College of Cardiology, 43 6
L. Finci, S. Silber, E. Grube, J. Belardi, J. Ormiston, B. Strauss, G. Guagliumi, M. Russell, A. Colombo (2004)
1044-56 Paclitaxel-eluting stent in complicated lesions or patient subsets: A subanalysis from the TAXUS II studyJournal of the American College of Cardiology, 43
A. Gershlick, I. Scheerder, B. Chevalier, A. Stephens-Lloyd, E. Camenzind, C. Vrints, N. Reifart, L. Missault, J. Goy, J. Brinker, A. Raizner, P. Urban, A. Heldman (2004)
Inhibition of Restenosis With a Paclitaxel-Eluting, Polymer-Free Coronary Stent: The European evaLUation of pacliTaxel Eluting Stent (ELUTES) TrialCirculation: Journal of the American Heart Association, 109
Huang Huang, Salu Salu, Liu Liu (2003)
Local stent‐mediated methotrexate delivery reduces neointimal hyperplasia in a porcine coronary modelAm J Cardiol, 92
G. Meireles, P. Lemos, J. Ambrose, E. Ribeiro, P. Horta, M. Perin, J. Ramires, E. Martinez (2004)
Luminal recovery from six to twelve months after implantation of "thicker strut" coronary stents.The American journal of cardiology, 93 2
G. Dussaillant, G. Mintz, A. Pichard, K. Kent, L. Satler, J. Popma, S. Wong, M. Leon (1995)
Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis.Journal of the American College of Cardiology, 26 3
E. Grube, S. Sonoda, F. Ikeno, Y. Honda, S. Kar, Charles Chan, U. Gerckens, A. Lansky, P. Fitzgerald (2004)
Six- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable PolymerCirculation: Journal of the American Heart Association, 109
S. Silber, J. Hamburger, E. Grube, M. Pfisterer, J. Belardi, J. Webb, K. Żmudka, C. Nienaber, Karl Hauptman, W. Rutsch, K. Dawkins, J. Drzewiecki, J. Koglin, A. Colombo (2004)
Direct Stenting with TAXUS Stents Seems to be as Safe and Effective as with PredilatationHerz, 29
Alexandre Abizaid, M. Albertal, M. Costa, A. Abizaid, R. Staico, F. Feres, L. Mattos, A. Sousa, J. Moses, Nicholas Kipshidize, G. Roubin, R. Mehran, G. New, Martin Leon, J. Sousa (2004)
First human experience with the 17-beta-estradiol-eluting stent: the Estrogen And Stents To Eliminate Restenosis (EASTER) trial.Journal of the American College of Cardiology, 43 6
J. Hodgson, R. Bottner, L. Klein, H. Walpole, D. Cohen, D. Cutlip, R. Fenninger, B. Firth, D. Greenberg, Ilona Kalisky, T. Meskan, W. Powell, G. Stone, James Zito, M. Clark (2004)
Drug‐eluting stent task force: Final report and recommendations of the working committees on cost‐effectiveness/economics, access to care, and medicolegal issuesCatheterization and Cardiovascular Interventions, 62
A. Lansky, R. Costa, G. Mintz, Y. Tsuchiya, M. Midei, D. Cox, C. O'shaughnessy, Robert Applegate, L. Cannon, M. Mooney, A. Farah, M. Tannenbaum, S. Yakubov, D. Kereiakes, S. Wong, B. Kaplan, Ecaterina Cristea, G. Stone, M. Leon, W. Knopf, W. O’Neill (2004)
Non–Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions: Angiographic Follow-Up of the DELIVER Clinical TrialCirculation: Journal of the American Heart Association, 109
M. Morice, P. Serruys, J. Sousa, J. Fajadet, E.Ban Hayashi, M. Perin, A. Colombo, G. Schuler, P. Barragan, G. Guagliumi, F. Molnár, R. Falotico (2002)
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.The New England journal of medicine, 346 23
E. Grube, S. Silber, K. Hauptmann, R. Mueller, L. Buellesfeld, U. Gerckens, M. Russell (2003)
TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary LesionsCirculation: Journal of the American Heart Association, 107
T. Yamawaki, H. Shimokawa, T. Kozai, K. Miyata, T. Higo, Eriko Tanaka, K. Egashira, Tadayoshi Shiraishi, Hideo Tamai, K. Igaki, Akira Takeshita (1998)
Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo.Journal of the American College of Cardiology, 32 3
M. Morice, P. Serruys, C. Costantini, E. Wuelfert, W. Wijns, J. Fajadet, A. Columbo, G. Guagliumi, F. Molnár, E.Ban Hayashi, J. Sousa, M. Perin (2003)
Two-year follow-up of the RAVEL study: A randomized study with the sirolimus-eluting Bx VELOCITY stent in the treatment of patients with denovo native coronary artery lesionsJournal of the American College of Cardiology, 41
A. Colombo, J. Drzewiecki, A. Banning, E. Grube, K. Hauptmann, S. Silber, D. Dudek, S. Fort, F. Schiele, K. Zmudka, G. Guagliumi, M. Russell (2003)
Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery LesionsCirculation: Journal of the American Heart Association, 108
J. Moses, M. Leon, J. Popma, P. Fitzgerald, D. Holmes, C. O'shaughnessy, R. Caputo, D. Kereiakes, David Williams, P. Teirstein, Judith Jaeger, R. Kuntz (2003)
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.The New England journal of medicine, 349 14
F. Vogt, A. Stein, G. Rettemeier, N. Krott, R. Hoffmann, A. Bosserhoff, W. Michaeli, Sasan Habibi-Naini, R. Blindt (2003)
A novel biodegradable coronary polymer stent with drug delivery capacities: Pacitaxeal loading inhibits neointimal hyperplasia in a porcine model of coronary restenosisJournal of the American College of Cardiology, 41
Heldman Heldman, Farhat Farhat, Fry Fry (2002)
Paclitaxel‐eluting stent for cytostatic prevention of restenosis: Patency study follow‐upAm J Cardiol, 90
(2004)
Bericht der Arbeitsgruppe Krankenhauswesen der Arbeitsgemeinschaft der obersten Landesgesundheitsbehörden der Länder (AOLG)
J. Schofer, M. Schlüter, A. Gershlick, W. Wijns, Eulogio García, E. Schampaert, G. Breithardt (2003)
Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS)The Lancet, 362
F. Versaci, A. Gaspardone, F. Tomai, F. Ribichini, P. Russo, I. Proietti, A. Ghini, V. Ferrero, L. Chiariello, P. Gioffrè, F. Romeo, F. Crea (2002)
Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study).Journal of the American College of Cardiology, 40 11
(2003)
Evaluation of a tacrolimus-eluting coronary stent graft for treatment of saphenous vein graft lesions: Procedural and 6-month follow-up results of the EVIDENT trial
M. Loutfi, N. Mulvihill, M. Boccalatte, B. Farah, J. Fajadet, J. Marco (2003)
Impact of restenosis and disease progression on clinical outcome after multivessel stenting in diabetic patientsCatheterization and Cardiovascular Interventions, 58
(2003)
First clinical experience with the Tacrolimus-Eluting Janus carbostent in de novo coronary arteries: The Jupiter I Study
P. Lemos, P. Serruys, E. Sousa (2003)
Drug‐Eluting Stents: Cost Versus Clinical BenefitCirculation, 107
D. Orlic, E. Bonizzoni, G. Stanković, F. Airoldi, A. Chieffo, N. Corvaja, G. Sangiorgi, Massimo Ferraro, C. Briguori, M. Montorfano, M. Carlino, A. Colombo (2004)
Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results.Journal of the American College of Cardiology, 43 7
竹林 秀雄 (2004)
Immediate and 3-month follow-up outcome after cutting balloon angioplasty for bifurcation lesions
J. Moses, M. Leon, J. Popma, Sidney Cohen, R. Kuntz (2004)
862-1 Matched comparison of direct stenting to predilation with the sirolimus-eluting by velocity™ stentJournal of the American College of Cardiology, 43
Sousa, R. Falotico, Judith Jaeger, J. Popma, P. Serruys, S. Abizaid, L. Tanajura, K. Kozuma, G. Langenhove, R. AmandaG.M., J. Sousa, M. Costa, A. Abizaid, B. Rensing (2001)
Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-UpCirculation: Journal of the American Heart Association, 104
(2003)
The first clinical experience with a reopro-coated coronary stent
K. Tanabe, P. Serruys, M. Degertekin, G. Guagliumi, E. Grube, Charles Chan, T. Munzel, J. Belardi, W. Rużyłło, L. Bilodeau, H. Kelbaek, J. Ormiston, K. Dawkins, L. Roy, B. Strauss, C. Disco, J. Koglin, M. Russell, A. Colombo (2004)
Chronic Arterial Responses to Polymer-Controlled Paclitaxel-Eluting Stents: Comparison With Bare Metal Stents by Serial Intravascular Ultrasound Analyses: Data From the Randomized TAXUS-II TrialCirculation: Journal of the American Heart Association, 109
S. Silber, E. Grube, P. Fitzgerald (2001)
The Quanam QuaDDS-QP2 Stent
T. Tsuji, H. Tamai, K. Igaki, E. Kyo, K. Kosuga, T. Hata, Takuji Nakamura, S. Fujita, S. Takeda, S. Motohara, H. Uehata (2003)
Biodegradable stents as a platform to drug loadingInternational Journal of Cardiovascular Interventions, 5
A. Ferreira, A. Peter, T. Salerno, H. Bolooki, E. Marchena (2003)
Clinical impact of drug-eluting stents in changing referral practices for coronary surgical revascularization in a tertiary care center.The Annals of thoracic surgery, 75 2
(2004)
ARTS II: First clinical results. EuroPCR Paris, late breaking trials
G. Stone, S. Ellis, D. Cox, J. Hermiller, C. O'shaughnessy, J. Mann, M. Turco, R. Caputo, P. Bergin, Joel Greenberg, J. Popma, M. Russell (2004)
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.The New England journal of medicine, 350 3
F. Liistro, G. Stanković, C. Mario, T. Takagi, A. Chieffo, S. Moshiri, M. Montorfano, M. Carlino, C. Briguori, P. Pagnotta, R. Albiero, N. Corvaja, A. Colombo (2002)
First Clinical Experience With a Paclitaxel Derivate–Eluting Polymer Stent System Implantation for In-Stent Restenosis: Immediate and Long-Term Clinical and Angiographic OutcomeCirculation: Journal of the American Heart Association, 105
N. Kipshidze, H. Kim, P. Iversen, H. Yazdi, B. Bhargava, G. New, R. Mehran, F. Tio, C. Haudenschild, G. Dangas, G. Stone, S. Iyer, G. Roubin, M. Leon, J. Moses (2002)
Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model.Journal of the American College of Cardiology, 39 10
D. Cutlip, M. Chauhan, D. Baim, K. Ho, J. Popma, J. Carrozza, D. Cohen, R. Kuntz (2002)
Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials.Journal of the American College of Cardiology, 40 12
A. Hoye, K. Tanabe, P. Lemos, J. Aoki, F. Saia, C. Arampatzis, M. Degertekin, S. Hofma, G. Sianos, E. Mcfadden, W. Giessen, P. Smits, P. Feyter, R. Domburg, P. Serruys (2004)
Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions.Journal of the American College of Cardiology, 43 11
S. Silber (2003)
Paclitaxel-eluting stents: are they all equal? An analysis of six randomized controlled trials in de novo lesions of 3,319 patients.Journal of interventional cardiology, 16 6
P. Lemos, F. Saia, J. Ligthart, C. Arampatzis, G. Sianos, K. Tanabe, A. Hoye, M. Degertekin, J. Daemen, E. Mcfadden, S. Hofma, P. Smits, P. Feyter, W. Giessen, R. Domburg, P. Serruys (2003)
Coronary Restenosis After Sirolimus‐Eluting Stent Implantation: Morphological Description and Mechanistic Analysis From a Consecutive Series of CasesCirculation, 108
S. Silber (2002)
[Antiproliferative coated stents and intracoronary brachytherapy: common traits and differences].Zeitschrift fur Kardiologie, 91 6
J. Goy, P. Urban, C. Seydoux, E. Benedetti, J. Stauffer (2004)
Use of sirolimus‐eluting coronary stents in routine clinical practiceCatheterization and Cardiovascular Interventions, 62
P. Serruys (1997)
Handbook of Coronary Stents
(2002)
Experimental and Preliminary Clinical Results with Batimastat. Drug-Eluting Stents
Xiaoshun Liu, Yanming Huang, C. Hanet, M. Vandormael, V. Legrand, J. Dens, J. Vandenbossche, L. Missault, C. Vrints, I. Scheerder (2003)
Study of antirestenosis with the BiodivYsio dexamethasone‐eluting stent (STRIDE): A first‐in‐human multicenter pilot trialCatheterization and Cardiovascular Interventions, 60
M. Kutryk, D. Foley, M. brand, J. Hamburger, W. Giessen, P. deFeyter, N. Bruining, M. Sabaté, P. Serruys (2002)
Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial.Journal of the American College of Cardiology, 39 2
(2003)
Carvedilol-coated coronary stent prevents porcine coronary stent restenosis
A. Kastrati, A. Schömig, S. Elezi, H. Schühlen, J. Dirschinger, M. Hadamitzky, A. Wehinger, J. Hausleiter, H. Walter, Franz‐Josef Neumann (1997)
Predictive factors of restenosis after coronary stent placement.Journal of the American College of Cardiology, 30 6
(2002)
One year follow-up of TAXUS-I: A randomized study with the paclitaxeleluting NIR conformer stent. Circulation, 2002;107:II394
J. Gunn, A. Morton, C. Wales, C. Newman, D. Crossman, D. Cumberland (2003)
Drug eluting stents: maximising benefit and minimising costHeart, 89
(2003)
ASPECT Study: 2-year follow-up of a polymer-free paclitaxel-eluting coronary stent
V. Poyen, M. Silvestri, P. Labrunie, B. Valeix (2003)
Indications of coronary angioplasty and stenting in 2003: what is left to surgery?The Journal of cardiovascular surgery, 44 3
(2004)
Durable clinical benefit following CYPHER coronary stent deployment : SIRIUS study 2 - year results
S. Silber, E. Grube (2001)
THE BOSTON SCIENTIFIC ANTIPROLIFERATIVE , PACLITAXEL ELUTING STENTS ( TAXUS )
(2004)
EuroPCR Paris, late breaking trials, oral presentation
H. Emanuelsson, K. Beatt, J. Bagger, R. Balcon, J. Heikkilä, J. Piessens, M. Schaeffer, H. Suryapranata, M. Foegh (1995)
Long-term Effects of Angiopeptin Treatment in Coronary Angioplasty Reduction of Clinical Events but Not Angiographic RestenosisCirculation, 91
P. Teirstein, R. Kuntz (2001)
New Frontiers in Interventional CardiologyCirculation, 104
G. New, J. Moses, G. Roubin, M. Leon, A. Colombo, S. Iyer, F. Tio, R. Mehran, N. Kipshidze (2002)
Estrogen‐eluting, phosphorylcholine‐coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary modelCatheterization and Cardiovascular Interventions, 57
J. Hodgson, S. King, T. Feldman, M. Cowley, L. Klein, J. Babb (2003)
SCAI statement on drug‐eluting stents: Practice and health care delivery implicationsCatheterization and Cardiovascular Interventions, 58
F. Vogt (2003)
P2237 A novel biodegradable coronary polymer stent with drug-delivery capacities: paclitaxel-loading inhibits neointimal hyperplasia in a porcine model of coronary restenosisEuropean Heart Journal, 24
H. Krumholz (1996)
Interventional Cardiology in Europe.NEJM Journal Watch, 1996
J. Sousa, P. Serruys, M. Costa (2003)
New frontiers in cardiology: drug-eluting stents: Part I.Circulation, 107 17
Y. Hongo, R. Sakurai, I. Meredith, R. Whitbourn, J. Ormiston, P. Key, D. Muller, M. Pitney, C. Aroney, M. Adams, A. Hassan, Y. Honda, P. Yock, P. Fitzgerald (2004)
1139-59 Intravascular ultrasound analysis of the new ABT-578 eluting phosphorylcholine-coated stent implantation to de novo human coronary lesions: The ENDEAVOR I trialJournal of the American College of Cardiology, 43
D. Greenberg, A. Bakhai, D. Cohen (2004)
Can we afford to eliminate restenosis? Can we afford not to?Journal of the American College of Cardiology, 43 4
P. Lemos, P. Serruys, R. Domburg, F. Saia, C. Arampatzis, A. Hoye, M. Degertekin, K. Tanabe, J. Daemen, Tommy Liu, E. Mcfadden, G. Sianos, S. Hofma, P. Smits, W. Giessen, P. Feyter (2004)
Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”: The R apamycin-E luting S tent E valuated A t R otterdam C ardiology H ospital (RESEARCH) RegistryCirculation: Journal of the American Heart Association, 109
(2003)
The DELIVER Trial: A randomized comparison of paclitaxel-coated versus metallic stents for treatment of coronary lesions
D. Cohen, A. Bakhai, C. Shi, Louise Githiora, R. Berezin, R. Caputo, Charles O'Shaugnessy, M. Leon, J. Moses, R. Kuntz (2003)
Cost-effectiveness of sirolimus drug-eluting stents for the treatment of complex coronary stenoses: Results from the randomized SIRIUS trialJournal of the American College of Cardiology, 41
Silber Silber, Hauptmann Hauptmann, Grube Grube (2002)
One year follow‐up of TAXUS‐I: A randomized study with the paclitaxel‐eluting NIR conformer stentCirculation, 107
T. Kataoka, E. Grube, Y. Honda, Y. Morino, S. Hur, H. Bonneau, A. Colombo, C. Mario, G. Guagliumi, K. Hauptmann, M. Pitney, A. Lansky, S. Stertzer, P. Yock, P. Fitzgerald (2002)
7-Hexanoyltaxol–Eluting Stent for Prevention of Neointimal Growth: An Intravascular Ultrasound Analysis From the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE)Circulation: Journal of the American Heart Association, 106
S. Silber, P. Albertsson, F. Avilés, P. Camici, A. Colombo, C. Hamm, E. Jørgensen, J. Marco, J. Nordrehaug, W. Rużyłło, P. Urban, G. Stone, W. Wijns (2005)
[Guidelines for percutaneous coronary interventions].Revista espanola de cardiologia, 58 6
A. Colombo, J. Moses, M. Morice, J. Ludwig, D. Holmes, V. Spanos, Y. Louvard, Benny Desmedt, C. Mario, M. Leon (2004)
Randomized Study to Evaluate Sirolimus-Eluting Stents Implanted at Coronary Bifurcation LesionsCirculation: Journal of the American Heart Association, 109
G. Stone, S. Ellis, D. Cox, J. Hermiller, C. O'shaughnessy, J. Mann, M. Turco, R. Caputo, P. Bergin, Joel Greenberg, J. Popma, M. Russell (2004)
One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent: The TAXUS-IV TrialCirculation: Journal of the American Heart Association, 109
S. Silber (2002)
Antiproliferativ beschichtete Stents und intrakoronare Brachytherapie: Gemeinsamkeiten und UnterschiedeZeitschrift für Kardiologie, 91
F. Saia, Pedro Lemos, C. Arampatzis, A. Hoye, E. Mcfadden, G. Sianos, P. Smits, W. Giessen, P. Feyter, R. Domburg, P. Serruys (2004)
CORONARY ARTERY DISEASE Original Studies Clinical and Angiographic Outcomes After Overdilatation of Undersized Sirolimus-Eluting Stents With Largely Oversized Balloons: An Observational Study
J. Sousa, P. Serruys, M. Costa (2003)
New frontiers in cardiology: drug-eluting stents: Part II.Circulation, 107 18
Y. Huang (2003)
P2239 Local stent mediated methotrexate delivery reduces neointimal hyperplasia in a porcine coronary modelEuropean Heart Journal, 24
In Europe, 1,108 percutaneous coronary interventions (PCIs) per one Mio inhabitants are currently annually performed, most of them with stent implantation. Drug‐eluting stents have been the focus of attention of interventional coronary therapy since the RAVEL study was first presented in September 2001 at the European Society of Cardiology Meeting. Ever since, numerous studies have assessed the effects of various antiproliferative and anti‐inflammatory substances and a variety of different stents was used as platform, either covered with polymer carriers of different chemical and physical properties or without a polymer carrier. CE‐ or FDA‐certified drug‐eluting stents are increasingly replacing the use of bare metal stents to reduce in‐stent restenosis. Today, physicians have a choice of several approved drug‐eluting stents and, therefore, need some evidence‐based guidance through the “jungle of information” to make the right decisions. Even when focusing on randomized trials, differences between the studies regarding primary endpoints and sample sizes exist, making it difficult to compare the various drug‐eluting stent studies. Randomized studies use either nonclinical (i.e., angiographic diameter stenosis, in‐stent MLD, or in‐stent late lumen loss) or clinical (i.e., TVF, TVR, and MACE) parameters as primary endpoints. Choosing an angiographic parameter as primary endpoint results in two major limitations: first, a significant improvement of an angiographic „surrogate” parameter does not necessarily translate into a better clinical outcome (DELIVER‐I); second, conclusions regarding possible improvements of clinical outcome are underpowered, because the sample size calculation is based on the primary endpoint. Usually the number of patients needed is lower for angiographic than for clinical endpoints. Until today, only three trials with a primary clinical endpoint have shown a significantly positive impact on patients' outcome: the SIRIUS trial (Cypher stent) with its reduction of primary endpoint TVF (21.0% vs 8.6%), the TAXUS‐IV trial (Taxus stent) with its reduction of primary endpoint TVR (12.0% vs 4.7%) and TAXUS‐VI in long lesions with its reduction of primary endpoint TVR (19.4% vs 9.1%). Although the angiographic results of other drug‐eluting stents are encouraging, they will have to prove their clinical impact based on adequately powered randomized trials with a primary clinical endpoint at an adequate time interval.
Journal of Interventional Cardiology – Wiley
Published: Dec 1, 2004
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.